59 results about "Polymersome" patented technology

The instant invention concerns compositions comprising polymersomes, visible or near infrared emissive agents, and optionally a targeting moiety associated with a surface of the polymersome. The invention also relates to use of these compositions in the treatment of disease and in imaging methodology.

The present invention provides biocompatible vesicles comprising semi-permeable, thin-walled encapsulating membranes which are formed in an aqueous solution, and which comprise one or more synthetic super-amphiphilic molecules. When at least one super-amphiphile molecule is a block copolymer, the resulting synthetic vesicle is termed a “polymersome.” The synthetic, reactive nature of the amphiphilic composition enables extensive, covalent cross-linking of the membrane, while maintaining semi-permeability. Cross-linking of the polymer building-block components provides mechanical control and long-term stability to the vesicle, thereby also providing a means of controlling the encapsulation or release of materials from the vesicle by modifying the composition of the membrane. Thus, the encapsulating membranes of the present invention are particularly suited for the reliable, durable and controlled transport, delivery and storage of materials.

Provided are methods for preparing and delivering stable, purely synthetic, self-assembling, controlled release, polyethylene oxide (PEO)-based polymersome vesicles, and the resulting PEO-based polymersomes capable of such controlled release, and methods of use therefor for the controlled transport and delivery of encapsulatable, cytotoxic, anticancer active agents contained therein. Further provided are methods for controlling destabilization of the vesicle membrane and the resulting hydrolysis-triggered, controlled release of active agent(s) encapsulated in the vesicle by controlling the blend ratio (mol %) of hydrolysable PEO-block copolymer of the hydrophilic component(s) and of the more hydrophobic PEO-block copolymer component(s) to produce amphiphilic high molecular weight PEO-based polymersomes, wherein the PEO volume fraction (f_EO) and chain chemistry control encapsulant release kinetics from the copolymer vesicles and the polymersome carrier membrane destabilization.

The present invention relates to methods and compositions for treating subterranean formations. More particularly, the present invention relates to polymersomes, viscosifying agents that comprise polymersomes, and associated methods of use. In some embodiments, the present invention discloses methods of treating a section of a subterranean formation that comprises the steps of providing a viscosified treatment fluid that comprises an aqueous-based component, and a viscosifying agent that comprises a polymersome; and treating the section of the subterranean formation. In other embodiments, the present invention discloses methods of viscosifying a treatment fluid, suspending particulates in a treatment fluid, fracturing a subterranean formation, providing sand control in a section of a subterranean formation, and encapsulating treatment fluid additives. In yet other embodiments, the present invention discloses viscosified treatment fluids, fracturing fluids, gravel pack fluids, polymersomes, and encapsulated treatment fluid additives.

The invention relates to an amphipathic block polymer, a polymersome consisting of the amphipathic block polymer, and a preparation method and application of the polymersome. More specifically, the amphipathic block polymer is obtained from a hydrophilic chain segment and a hydrophobic chain segment by a reversible addition-fragmentation chain transfer (RAFT) polymerization method, wherein the hydrophilic chain segment is polyethylene glycol with the terminal group modified by tri-thioester and the molecular weight of the hydrophilic chain segment is 1,000 to 20,000 Da; the constitution of the hydrophobic chain segment is as shown in the following formula, m is equal to 1 to 11 and n is equal to 1 to 11. By adoption of the amphipathic block polymer, controllable and synchronous release of polymersome-loaded hydrophilic and hydrophobic molecules is realized, and the biological catalytic activity of a polymersome-loaded enzyme reactor is regulated and controlled through stimulation. In addition, in the processing of triggering crosslinking by stimulation, the permeability of a sieve-shaped hydrophilic channel generated in a double-layer membrane of the polymersome and the membrane can be controlled by the duration time of stimulation.

Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

The invention discloses a reversibly crosslinked biodegradable polymersome with an asymmetric membrane structure as well as a preparation method and application thereof to nucleic acid medicines. The polymersome and the preparation method have the advantages that a triblock polymer PEG-P(TMC-DTC)-PEI or PEG-P(DLLA-DTC)-PEI is synthesized and is self-assembled and self-crosslinked to obtain the polymersome with the asymmetric membrane structure or the triblock polymer is linked with a targeting molecule and is self-assembled to obtain targeting RCCPs; the inner shell of the polymersome is PEI and is used for compounding and loading nucleic acid through electrostatic interaction; a membrane is reversibly crosslinked biodegradable polyester/polycarbonate with good biocompatibility; dithiolane of a side chain is similar to a human body natural antioxidant lipoic acid; the outer shell of the polymersome takes PEG as the background and can target cancer cells; by studying that the carrier is compounded with functional siRNA and studying the gene silencing effects in vitro and vivo, in vivo blood circulation and bio-distribution, the condition of treating lung cancer in situ bearing mice and toxic and side effects of the polymersome, the polymersome is expected to become a nanosystem platform integrating the advantages of simplicity, stability, multifunction, and the like and is used for carrying out efficient and active targeting delivery on siRNA to tumors in situ.

Provided are polymer vesicles comprising polymersomes, a radiofrequency absorbing moiety, a protein or a polysaccharide associated with the inner leaflet of the membrane and a therapeutic or diagnostic cargo. The invention also concerns the use of these polymer vesicles for selective electromagnetic energy-induced delivery of therapeutic or diagnostic agents.

The invention relates to a DCs vaccine based on phospholipid hybrid polymersome jointly encapsulating an antigen and dual immunoagonists, a preparation method and application thereof. The phospholipidhybrid polymersome which can jointly load a model antigen OVA and two types of TLR agonists (TLR7/8 and TLR4) is used for stimulation in vitro of the DCs so as to realize the effective phagocytosis of DCs cells. The rapid and long-term immunostimulatory effect on the DCs is achieved by the internal and external co-loading of the OVA antigen. The synergistic effect of the two types of TLR agonistssignificantly enhances the immune response after antigen stimulation; the phospholipid hybrid polymersome which jointly encapsulates the antigen and the dual immunoagonists can effectively promote the activation and maturation of the DCs, increases the level of cross-presentation, promotes the migration of the DC vaccine to secondary lymphoid organs, and produces a strong specific cytotoxic T lymphocytes (CTLs) killing effect, thereby effectively killing tumor cells and realizing the immunotherapy of the DCs vaccine on tumors.

The invention provides a block copolypeptide comprising a hydrophilic heteropolypeptide block (A) and a hydrophobic homopolypeptide block (B). There is also provided a polymersome comprising a block copolypeptide of the invention. The invention further provides a method for preparing a copolymer comprising ring-opening polymerisation (ROP) of an amino acid N-carboxyanhydride (NCA) initiated from a peptide.

A cosmetic composition for improving skin elasticity is provided which contains an active ingredient in the form of a polymersome in which Phyllanthus urinaria extract and an anti-ageing peptide have been stabilised on the inside. The cosmetic composition of the present invention is efficacious in improving skin wrinkles, restoring skin elasticity and increasing the skin water content, and is effective in improving skin elasticity.

Provided is a biocompatible polyethylene oxide (PEO)-based polymersome system for the delivery of oligonucleotides, including antisense RNA, siRNA and RNAi, to a cell or tissue target, and method of use therefore, wherein the method comprises encapsulating the oligonucleotide in a biodegradable neutral, nano-transforming polymersome delivery vehicle and delivering the encapsulated oligonucleotide to the cell or tissue target in vitro or in vivo, particularly for treating a disease, such cancer or cellular hyperproliferation. The degradable polymersome, and the oligonucleotides stably encapsulated therein are taken up passively by cells and delivered into endolysosomes, wherein the polymersomes decompose at a known rate at a known pH, thereby releasing encapsulated oligonucleotides in a controlled manner within the cell and facilitating delivery of antisense oligonucleotide or siRNA or RNAi into the nucleus of the cell target.

The invention discloses application of a reduction response polymersome nano-drug in preparation of brain tumor treatment drugs. Block copolymers PEG-P(TMC-DTC), PEG-P(LA-DTC), PEG-P(TMC-DTC)-PEI, PEG-P(LA-DTC)-PEI, PEG-P(TMC-DTC)-Sp, PEG-P(LA-DTC)-Sp and targeted polymers thereof are combined in different ratios, and dual-targeted reduction-sensitive reversible crosslinked vesicles of different targeted molecular proportions can be prepared. Through the hydrogen-bond interaction or other electrostatic interaction between great hydrophilic inner cavities of the crosslinked vesicles and/or PEI-spermine and protein drugs or gene drugs, efficient encapsulation of micromolecular chemotherapeutic drugs, the protein drugs and the gene drugs can be achieved. By means of the in-vivo dual-targeteddrug-carrying crosslinked vesicles, more efficient blood brain barrier crossing, higher tissue penetration depth and endocytosis of more glioma cells can be achieved, and the reduction response polymersome nano-drug is very potential in treating brain gliomas and efficient.

The invention discloses a polymersome with a hydrophilic lumen carrying anthracene ring medicines as well as a preparation method and an application. The preparation method comprises the following steps: (1) dissolving a PCL-b-PEG-b-PCL amphiphilic triblock copolymer in an organic solvent, carrying out rotary evaporation in a rotary evaporator to remove the organic solvent, forming a layer of uniform film on the inner wall of an eggplant-shaped bottle, and drying the film; (2) adding an ammonium sulfate water solution, carrying out hydration, oscillating the materials to mix the materials uniformly, and carrying out ultrasonic treatment in an ice bath to obtain a stable blank polymersome dispersion liquid; (3) dialyzing the blank polymersome dispersion liquid; (4) dissolving water-soluble anthracene ring medicines in deionized water, adding the solution to the blank polymersome dispersion liquid, and stirring the solution; cooling the product to the room temperature and dialyzing the product, thus obtaining the polymersome with the hydrophilic lumen carrying the anthracene ring medicines. The polymersome has good in vivo and in vitro stability and higher entrapment efficiency and effectively gathers on tumor sites, thus achieving the aim of targeted therapy.

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen.

It is an object of the invention to provide a polymersome excellent in the safety and feeling in use; in particular, there is no sticky feeling but there is a good refreshing feeling; and with excellent base-agent stability. A polymersome of the present invention comprises a block-type alkylene oxide derivative represented by the following formula (I) as the membrane component:

R¹O-[(EO)_I(AO)_m(EO)_n]-R²   (I)

wherein AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, m and 1+n are the average addition mole numbers for the oxyalkylene group and the oxyethylene group, respectively, and 1≦m≦70, 1≦1+n≦70; the percentage of the oxyethylene groups with respect to the sum of the oxyalkylene groups having 3 to 4 carbon atoms and the oxyethylene groups is 20 to 80 mass %; the addition pattern of the oxyalkylene groups having 3 to 4 carbon atoms and the oxyethylene groups is block-type; and R¹ and R² are identical or different hydrocarbon groups having 1 to 4 carbon atoms.

The present invention provides for delivery of therapeutic drug in a polymeric delivery system comprising a PEG-bl-PPS di-block polymer formed in a micelle, filomicelle, or polymersome structure, wherein the structure effectively binds and/or interacts through shape-based targeting with a targeted cell type.

Provided are polymersomes for co-delivery of hydrophobic metallic nanoparticles and pharmaceutical agents and suspensions of such polymersomes. Also provided are methods of making such polymersomes and suspensions of polymersome and methods of using the same to treat diseases or conditions.

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.